论文部分内容阅读
目的:观察生芪颗粒干预胰岛素抵抗大鼠血清ET-1、AngⅡ和心脏AT1等指标水平变化,探讨中药对胰岛素抵抗血管内皮功能的影响机制。方法:选用健康雄性Wistar大鼠60只,按随机数字表法分为6组:生芪颗粒低、中、高剂量组、罗格列酮组、正常组和模型组。正常组和模型组给予枸椽酸钠溶液。生芪颗粒低、中、高剂量组以人鼠单位体重用药量直接换算后剂量的5,10,20倍灌胃生芪颗粒溶液。罗格列酮组:灌胃100 g/L的马来酸罗格列酮悬浊液。测定治疗前后血清ET-1、AngⅡ变化;免疫组化法测定治疗前后心脏AT1的变化。结果:生芪颗粒高剂量组、罗格列酮组血清ET-1、AngⅡ与正常组比较均无显著差异(P>0.05),生芪颗粒中、高剂量组、罗格列酮组血清ET-1、AngⅡ与模型组存在显著差异(P<0.05);生芪颗粒各组、罗格列酮组、模型组心脏AT1和正常组比较均有显著性差异(P<0.05),与模型组相比,生芪颗粒中、高剂量组和罗格列酮组均有明显的下降(P<0.05)。结论:生芪颗粒可降低胰岛素抵抗大鼠血清ET-1、AngⅡ和心脏AT1的免疫组化表达,作用效果与罗格列酮相当,并呈剂量依赖性。
OBJECTIVE: To observe the changes of serum ET-1, Ang II and cardiac AT1 levels in rats with insulin resistance after intervention with Shengqi granules, and to explore the mechanism of traditional Chinese medicine on the vascular endothelial function of insulin resistance. METHODS: A total of 60 healthy male Wistar rats were randomly divided into 6 groups according to the random number table: low, medium, and high doses of oxime granules, rosiglitazone, normal, and model groups. Sodium citrate solution was given to normal and model groups. In the low, medium, and high dose groups of raw wolfberry particles, the doses of human and mouse body weights were directly converted to 5, 10, and 20 times the doses of gavage oyster granule solution. Rosiglitazone group: 100 g/L rosiglitazone maleate suspension. Serum ET-1 and AngII levels were measured before and after treatment. Immunohistochemistry was used to measure changes in cardiac AT1 before and after treatment. RESULTS: There was no significant difference in serum concentration of ET-1 and AngII between the high-dose group and the rosiglitazone group compared with the normal group (P>0.05). The serum ET of the high-dose group and high-dose group of Shengqi granules and rosiglitazone group There was a significant difference between AngII and model group (P<0.05). There was significant difference between AngII group, rosiglitazone group and model group AT1 and normal group (P<0.05). In comparison, there was a significant decrease in the middle and high-dose group and rosiglitazone group (P<0.05). CONCLUSION: Shengqi granules can reduce the expression of ET-1, AngII and cardiac AT1 in insulin resistant rats. The effect is similar to that of rosiglitazone in a dose-dependent manner.